Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00061425 | Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG | PHASE1 | COMPLETED | - | — | — | Aug 1, 2000 | - | Aug 19, 2021 | - | — |
| Name | Type | Description |
|---|---|---|
| radiolabeled epratuzumab | DRUG | - |
Inclusion: * Histological or cytological diagnosis of B-cell lymphoma, and has failed at least one regimen of standard chemotherapy. (All histological grades of NHL will be eligible for this trial.) * Measureable via CT, with at least one lesion \> or = 1.5cm in one or both dimensions. (Splenic tum...